AIM: The aim of this retrospective study was to analyze data for @entity1 with stage @entity5 who were treated with concurrent chemoradiotherapy with @entity1487 ( @entity1487 ) and @entity900 (CCRT-FP) as postoperative adjuvant therapy and to re-examine these issues and further treatment. METHODS: @entity1 with high risk for recurrence underwent CCRT-FP as postoperative adjuvant therapy. A total of 73 @entity1 who met these criteria were included in this study. Data related to survival, @entity137 , and treatment feasibility were analyzed, and the question of whether there were differences in survival and @entity137 according to the number of dissected lymph nodes at surgery was evaluated. RESULTS: Median @entity1 age was 45   years (range, 24-67 years). Two-thirds of @entity1 had squamous cell histologic type, 41 @entity1 (56.2%) had parametrial invasion, and 60 @entity1 (82.2%) had lymph node @entity3 . Estimated 4-year progression-free survival, overall survival, and local control rates were 71.8%, 84.1%, and 88.5%, respectively. Sixteen @entity1 (21.9%) had grade 3-4 @entity1398 and one of them died of @entity326 . @entity1503 were also common: 13 (17.8%) experienced grade 3-4 @entity390 , and nine (12.3%) experienced grade 3-4 @entity294 . @entity2616 occurred in 17 @entity1 (23.3%), and seven of them (9.6%) were not yet cured. One @entity1 experienced @entity344 . CONCLUSIONS: CCRT-FP in the postoperative setting resulted in good survival outcome but @entity137 remained problematic. Development of appropriate treatment for @entity1 with high-risk prognostic factors after radical hysterectomy and lymphadenectomy is required.

Reconsideration of postoperative concurrent chemoradiotherapy with XXXX and @entity900 for uterine cervical @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity326 :: ('MESH:D012772', 'Disease') :: ['septic shock'] @entity5 :: ('MESH:D009369', 'Disease') :: ['IB-IIB uterine cervical cancer'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2616 :: ('MESH:D045823', 'Disease') :: ['Ileus'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal perforation'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['Non-hematological toxicities'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', 'fluorouracil']
@entity1487 :: (MESH:D005472,Chemical) :: ['fluorouracil']
